General
Preferred name
MARAVIROC
Synonyms
UK-427857 ()
Selzentry ()
Celsentri ()
Uk-427,857 ()
Rel-Maraviroc ()
Maraviroc-d6 ()
P&D ID
PD016315
CAS
376348-65-1
Tags
natural product
drug
available
Drug Status
investigational
approved
Max Phase
Phase 4
First approval
2007
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
12
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
513.33
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
5
Aromatic Ring Count
2
cLogP
5.95
TPSA
63.05
Fraction CSP3
0.69
Chiral centers
4.0
Largest ring
6.0
QED
0.47
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
chemokine receptor antagonist
CCR antagonist
CC chemokine receptor antagonist
Target
C-C chemokine receptor type 5
MIP-1??
RANTES
MIP-1¦Á
MIP-1¦Â
CCR5
CCR
HIV
Pathway
Immunology/Inflammation
Microbiology&virology
Anti-infection
GPCR/G protein
Indication
human immunodeficiency virus (HIV-1)
Source data
